Why USANA (USNA) shares are sliding today

What happened

USANA Health Sciences reported a $5.6 million net loss and a 4% decline in third-quarter 2026 net sales, which fell to $206 million year over year. Adjusted EBITDA, a measure of operating earnings, fell 13% to $12.1 million, and the company projected full-year sales approaching $900 million and adjusted EBITDA of $77 million.

Confirmed

Global impact / market context

Lower sales and a net loss point to weaker demand or higher costs pressuring USANA’s results, while the fall in adjusted EBITDA, a measure of operating earnings before certain costs, suggests less earnings generated from its business. That can reduce confidence in its ability to meet its annual outlook.

Analyst inference

The article says USANA shares have made 18 moves greater than 5% over the past year, so a 4.4% decline is within a pattern of volatility. It also reports that an earlier quarterly results miss was followed by a 29.5% drop, indicating earnings news can prompt sharp repricing.

Confirmed

What to watch

1. Compare upcoming net sales with the company’s full-year projection of nearly $900 million; continued declines would make that target harder to reach and could pressure revenue expectations. Analyst inference
2. Watch whether adjusted EBITDA, a measure of operating earnings before certain costs, stabilizes after falling 13% year over year, since further weakness could signal ongoing cost or sales pressure. Analyst inference
3. Check future company updates for changes to 2026 guidance, especially sales and adjusted EBITDA, because the current projections are approaching $900 million and $77 million, respectively. Confirmed

Evidence

• stockstory.org